VTX-0811

• Description :

  VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma[1].

• UNSPSC :

  12352203

• Target :

  C-Myc; NF-κB; TNF Receptor

• Related Pathways :

  Apoptosis; NF-κB

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Smiles :

  [VTX-0811]

• References & Citations :

  [1]Feldman I, et al. VTX-0811, a first-in-class PSGL-1 blocking monoclonal antibody, repolarizes tumor associated macrophages and induces inflammation in the tumor microenvironment, leading to suppression of tumor growth in pre-clinical studies[J]. Cancer Research, 2022, 82 (12_Supplement) : 5602-5602.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  No Development Reported